EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lipid Profile, PCSK9 , ANGPTL3 and Lipoprotein (a) Levels in Men Diagnosed With Localized High‐Grade Prostate Cancer and Men At‐Risk of Prostate Cancer

Ann-Charlotte Bergeron, Emilie Wong-Chong iD, France-Hélène Joncas, Chloé Castonguay, Frédéric Calon, Nabil G Seidah, Jonatan Blais, Karine Robitaille, Alain Bergeron, Vincent Fradet, Anne Gangloff

Cancer Medicine · 2025

DOI: 10.1002/cam4.70587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Ann-Charlotte Bergeron und 10 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Research Axis, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, Quebec, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Proprotein Convertase 9, Lipoprotein(a), Angiopoietin-like Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation du CHU de Québec.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Some cancers have been found to require abundant supplies of lipids for their development. One example is prostate cancer (PCa). To date, lipid‐modifying factors, such as proprotein convertase subtilisin/kexin type 9 (PCSK9), angiopoietin‐like 3 protein (ANGPTL3), and lipoprotein(a) or Lp(a), have not been reported in men with PCa. The present study aimed to verify whether plasma levels of these lipid‐related proteins vary in men with PCa compared to at‐risk but cancer‐free men.

Methods

Plasma samples from 35 men with locally advanced PCa Gleason 8 and 9 versus 35 men at risk of PCa were selected as cases and controls. Blood samples were paired according to age and BMI. Apolipoprotein B100 (Apo B), Lp(a), and lipid profiles were measured on an analytical platform (Roche Cobas). PCSK9 and ANGPTL3 levels were determined by ELISA.

Results

No significant change in lipids and related factors levels was observed between men with localized PCa Gleason 8 or 9 and matched controls. A correlation between ANGPTL3 and HDL levels was only confirmed in controls (ρ = 0.54, p = 0.0009). PCSK9 was inversely associated with PSA levels in the entire cohort (ρ = −0.31, p < 0.01), suggesting that factors influencing PCSK9 could also influence PSA levels. In controls only, PSA levels were correlated with LDL, Apo B, non‐HDL, total cholesterol, and triglycerides (all ρ coefficients ≥ 0.35, all p ‐values < 0.05). PCSK9 was correlated to LDL in PCa men, but the relationship was unexpectedly found to be inverse.

Conclusions

In this observational study, lipid profiles, PCSK9, ANGPTL3, and Lp(a) levels did not change in men diagnosed with locally advanced Gleason 8 or 9 PCa compared to at‐risk but cancer‐free men. The present data suggest a complex interplay between PCSK9, PSA, and the lipid profile in localized PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProprotein Convertase 9Lipoprotein(a)Angiopoietin-like ProteinsLipidsHumansMaleAngiopoietin-Like Protein 3AgedMiddle AgedNeoplasm GradingCase-Control StudiesRisk Factors

Stichwörter der Autor:innen

ANGPTL3PCSK9lipid‐lowering drugs targetslipoprotein (a)prostate cancer

Substanzen

Angiopoietin-Like Protein 3ANGPTL3 protein, humanProprotein Convertase 9PCSK9 protein, humanLipoprotein(a)Angiopoietin-like ProteinsLipids

Autor:innen und Institutionen

  • Oncology Research Axis, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, Quebec, Canada.
  • Division of Molecular Medicine, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada.
  • Cancer Research Center (CRC), Université Laval, Quebec City, Quebec, Canada.
  • Institute of Nutrition and Functional Foods (INAF) and NUTRISS Center - Nutrition, Health and Society of Université Laval, Quebec City, Quebec, Canada.
  • Neuroscience Research Axis, Centre de Recherche du CHU de Québec-Université Laval, Quebec City, Quebec, Canada.
  • Laboratory of Biochemical Neuroendocrinology, Institut de Recherches Cliniques de Montréal, Montreal, Quebec, Canada.

ORCID-Profile: Emilie Wong-Chong

Förderung

  • Fondation du CHU de Québec

Zitieren

APA

Bergeron, A. C., Wong-Chong, E., Joncas, F. H., Castonguay, C., Calon, F., Seidah, N. G., Blais, J., Robitaille, K., Bergeron, A., Fradet, V., & Gangloff, A. (2025). Lipid Profile, PCSK9 , ANGPTL3 and Lipoprotein (a) Levels in Men Diagnosed With Localized High‐Grade Prostate Cancer and Men At‐Risk of Prostate Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70587

Vancouver

Bergeron AC, Wong-Chong E, Joncas FH, Castonguay C, Calon F, Seidah NG, et al. Lipid Profile, PCSK9 , ANGPTL3 and Lipoprotein (a) Levels in Men Diagnosed With Localized High‐Grade Prostate Cancer and Men At‐Risk of Prostate Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.70587

BibTeX
@article{Bergeron2025,
  author = {Bergeron, Ann-Charlotte and Wong-Chong, Emilie and Joncas, France-Hélène and Castonguay, Chloé and Calon, Frédéric and Seidah, Nabil G and Blais, Jonatan and Robitaille, Karine and Bergeron, Alain and Fradet, Vincent and Gangloff, Anne},
  title = {Lipid Profile, PCSK9 , ANGPTL3 and Lipoprotein (a) Levels in Men Diagnosed With Localized High‐Grade Prostate Cancer and Men At‐Risk of Prostate Cancer},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70587}
}
Kostenlos starten →